✦ LIBER ✦

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

✍ Scribed by Winnie Yeo; F. K. F. Mo; J. J. S. Suen; W. M. Ho; S. L. Chan; W. Lau; J. Koh; W. K. Yeung; W. H. Kwan; K. K. C. Lee; T. S. K. Mok; A. N. Y. Poon; K. C. Lam; E. K. Hui; B. Zee

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 184 KB
Volume: 113
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-9957-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Costs of uncontrolled chemotherapy-induc

Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy

✍ Ya-Chen Tina Shih; Ying Xu; Linda S. Elting 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract ## BACKGROUND. Chemotherapy‐induced nausea and vomiting (CINV) is among the most feared side effects of cancer treatment. Poorly controlled CINV may lead to additional office visits or emergency room admissions, thus increasing the overall costs of cancer care. The objective of the pro

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Aprepitant for the prevention of chemoth

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

✍ Bernardo L. Rapoport; Karin Jordan; Judith A. Boice; Arlene Taylor; Carole Brown 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 174 KB

Palonosetron plus dexamethasone for prev

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

✍ Lawrence H. Einhorn; Mary J. Brames; Robert Dreicer; Craig R. Nichols; Michael T 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 220 KB

Effectiveness of a single-day three-drug

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

✍ Steven M. Grunberg; Matthew Dugan; Hyman Muss; Marie Wood; Susan Burdette-Radoux 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 148 KB

Randomized, placebo-controlled, pilot st

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

✍ Jon D. Herrington; Adam D. Jaskiewicz; Juhee Song 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract ## BACKGROUND. The combination of palonosetron and aprepitant is safe and effective in the prevention of chemotherapy‐induced emesis (CIE). The purpose of this pilot study was to ascertain the effectiveness of 1‐day versus 3‐day aprepitant in the prevention of acute and delayed nausea